The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

St. Charles, Missouri, resident Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s ...